  The potential of large language models in medicine for education and decision
making purposes has been demonstrated as they achieve decent scores on medical
exams such as the United States Medical Licensing Exam (USMLE) and the MedQA
exam. In this work, we evaluate the performance of ChatGPT-4 in the specialized
field of radiation oncology using the 38th American College of Radiology (ACR)
radiation oncology in-training (TXIT) exam and the 2022 Red Journal Gray Zone
cases. For the TXIT exam, ChatGPT-3.5 and ChatGPT-4 have achieved the scores of
63.65% and 74.57%, respectively, highlighting the advantage of the latest
ChatGPT-4 model. Based on the TXIT exam, ChatGPT-4's strong and weak areas in
radiation oncology are identified to some extent. Specifically, ChatGPT-4
demonstrates better knowledge of statistics, CNS & eye, pediatrics, biology,
and physics than knowledge of bone & soft tissue and gynecology, as per the ACR
knowledge domain. Regarding clinical care paths, ChatGPT-4 performs better in
diagnosis, prognosis, and toxicity than brachytherapy and dosimetry. It lacks
proficiency in in-depth details of clinical trials. For the Gray Zone cases,
ChatGPT-4 is able to suggest a personalized treatment approach to each case
with high correctness and comprehensiveness. Importantly, it provides novel
treatment aspects for many cases, which are not suggested by any human experts.
Both evaluations demonstrate the potential of ChatGPT-4 in medical education
for the general public and cancer patients, as well as the potential to aid
clinical decision-making, while acknowledging its limitations in certain
domains. Because of the risk of hallucination, facts provided by ChatGPT always
need to be verified.
